A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Inclusion Criteria: * Adult patients, \>/= 21 years of age * Moderate to severe active rheumatoid arthritis (DAS28 \>/= 3.2) * Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) * Initiated on RoActemra/Actemra treatment in accordance with the prescribing information Exclusion Criteria: * Pregnant or lactating women * Contra-indication to RoActemra/Actemra treatment according to the local labelling * Previous treatment with tocilizumab * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra * Women of childbearing potential not using effective methods of contraception as defined by protocol